EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Real-world effectiveness and safety of dupilumab in children with atopic dermatitis: a Latin American single-center study

Victor Gonzalez-Uribe, Hector Rodrigo Pastrana-Ayala, Luis Angel Hernandez-Zarate, Carlos Andres Gomez-Nuñez, Maria Julia Rendon-Salazar, Tamara Hernandez-Hernandez, Ricardo Martinez-Tenopala, Zaira Selene Mojica-Gonzalez

Allergologia et Immunopathologia · 01.03.2026 · 54 (2) · 28-34

DOI: 10.15586/aei.v54i2.1402 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Allergologia et Immunopathologia, online erschienen am 01.03.2026. Verfasst von Victor Gonzalez-Uribe und 7 weiteren Autor:innen. Beteiligte Einrichtung: AlergiaMx, Benito Juarez, Mexico City, Mexico. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Gefördert von: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sector..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atopic dermatitis (AD) is common in children (affecting ~20% of children globally) and imposes a substantial burden. Many children in Latin America have moderate-to-severe AD with limited access to advanced therapies, highlighting an unmet need for safe and effective treatment options. Dupilumab, a targeted anti-interleukin-4 (IL-4)–IL-13 biologic, has demonstrated efficacy in pediatric AD, but real-world data in Latin American children are scarce.

Methods

We conducted a single-center retrospective observational study in Mexico City with children (aged 4–18 years) with moderate-to-severe AD treated with dupilumab from 2018 to 2024. Clinical outcomes (Eczema Area and Severity Index; Scoring Atopic Dermatitis [SCORAD], and pruritus Numerical Rating Scale [NRS]) and quality-of-life (Dermatology Life Quality Index) were assessed at baseline and ~3, ~6, and ~12 months. Changes over time were analyzed using nonparametric tests, and adverse events were documented.

Results

In all, 23 children (~50% female) with severe, treatment-refractory AD were included. Dupilumab led to rapid and significant improvement in all endpoints (P < 0.001). In 12 months, most patients achieved clear or almost clear skin with no pruritus (median SCORAD and itch NRS = 0), and quality-of-life scores improved from a median of 19 to 3. No serious adverse events occurred; mild conjunctivitis was reported in 13% patients (with one discontinuation).

Conclusion

In this Latin American pediatric cohort, dupilumab achieved marked and sustained improvements in disease severity and quality of life, with a favorable safety profile. This real-world study addresses a regional evidence gap and supports dupilumab as an effective and well-tolerated treatment for moderate-to-severe pediatric AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedHumansFemaleChildMaleChild, PreschoolAdolescentRetrospective StudiesTreatment OutcomeQuality of LifeSeverity of Illness IndexLatin AmericaMexico

Stichwörter der Autor:innen

Latin Americanatopic dermatitischildrendupilumabeffectivenessreal world

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • AlergiaMx, Benito Juarez, Mexico City, Mexico.
  • Facultad Mexicana de Medicina, Universidad La Salle Mexico, Tlalpan, Mexico City, Mexico; dr.victorgonzalezu@gmail.com.
  • Hospital Infantil de Mexico Federico Gomez, Cuauhtemoc, Mexico City, Mexico.
  • Facultad Mexicana de Medicina, Universidad La Salle Mexico, Tlalpan, Mexico City, Mexico.

Förderung

  • This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sector.

Zitieren

APA

Gonzalez-Uribe, V., Pastrana-Ayala, H. R., Hernandez-Zarate, L. A., Gomez-Nuñez, C. A., Rendon-Salazar, M. J., Hernandez-Hernandez, T., Martinez-Tenopala, R., & Mojica-Gonzalez, Z. S. (2026). Real-world effectiveness and safety of dupilumab in children with atopic dermatitis: a Latin American single-center study. Allergologia et Immunopathologia, 54(2), 28-34. https://doi.org/10.15586/aei.v54i2.1402

Vancouver

Gonzalez-Uribe V, Pastrana-Ayala HR, Hernandez-Zarate LA, Gomez-Nuñez CA, Rendon-Salazar MJ, Hernandez-Hernandez T, et al. Real-world effectiveness and safety of dupilumab in children with atopic dermatitis: a Latin American single-center study. Allergologia et Immunopathologia. 2026;54(2):28-34. doi:10.15586/aei.v54i2.1402

BibTeX
@article{GonzalezUribe2026,
  author = {Gonzalez-Uribe, Victor and Pastrana-Ayala, Hector Rodrigo and Hernandez-Zarate, Luis Angel and Gomez-Nuñez, Carlos Andres and Rendon-Salazar, Maria Julia and Hernandez-Hernandez, Tamara and Martinez-Tenopala, Ricardo and Mojica-Gonzalez, Zaira Selene},
  title = {Real-world effectiveness and safety of dupilumab in children with atopic dermatitis: a Latin American single-center study},
  journal = {Allergologia et Immunopathologia},
  year = {2026},
  volume = {54},
  number = {2},
  pages = {28--34},
  doi = {10.15586/aei.v54i2.1402}
}
Kostenlos starten →